EP1446008A4 - Compositions and methods for controlled release - Google Patents
Compositions and methods for controlled releaseInfo
- Publication number
- EP1446008A4 EP1446008A4 EP02803289A EP02803289A EP1446008A4 EP 1446008 A4 EP1446008 A4 EP 1446008A4 EP 02803289 A EP02803289 A EP 02803289A EP 02803289 A EP02803289 A EP 02803289A EP 1446008 A4 EP1446008 A4 EP 1446008A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- controlled release
- release
- controlled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Transplantation (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33634401P | 2001-10-18 | 2001-10-18 | |
US336344P | 2001-10-18 | ||
PCT/US2002/033558 WO2003060142A2 (en) | 2001-10-18 | 2002-10-17 | Compositions and methods for controlled release |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1446008A2 EP1446008A2 (en) | 2004-08-18 |
EP1446008A4 true EP1446008A4 (en) | 2006-08-16 |
Family
ID=23315656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02803289A Withdrawn EP1446008A4 (en) | 2001-10-18 | 2002-10-17 | Compositions and methods for controlled release |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1446008A4 (en) |
JP (1) | JP2005523890A (en) |
AU (1) | AU2002365136A1 (en) |
CA (1) | CA2464131A1 (en) |
WO (1) | WO2003060142A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009145813A1 (en) | 2008-03-04 | 2009-12-03 | Qd Vision, Inc. | Particles including nanoparticles, uses thereof, and methods |
CN102482457B (en) | 2009-09-09 | 2015-04-15 | Qd视光有限公司 | Particles including nanoparticles, uses thereof, and methods |
WO2011031876A1 (en) | 2009-09-09 | 2011-03-17 | Qd Vision, Inc. | Formulations including nanoparticles |
DE102009058769A1 (en) * | 2009-12-16 | 2011-06-22 | MagForce Nanotechnologies AG, 10589 | Temperature-dependent activation of catalytic nucleic acids for controlled drug release |
JP2016183434A (en) * | 2015-03-26 | 2016-10-20 | 国立大学法人京都大学 | Surface modification substrate |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998052614A2 (en) * | 1997-05-21 | 1998-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
US5985554A (en) * | 1994-11-02 | 1999-11-16 | Takeda Chemical Industries, Ltd. | Method of probing the function of proteins or peptides encoded by partially sequenced cDNAs by inhibiting protein synthesis with antisense oligonucleotides |
WO2001024775A1 (en) * | 1999-10-01 | 2001-04-12 | Essentia Biosystems, Inc. | Gel-forming compositions |
US6232068B1 (en) * | 1999-01-22 | 2001-05-15 | Rosetta Inpharmatics, Inc. | Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies |
US6333194B1 (en) * | 1999-01-19 | 2001-12-25 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
US6395029B1 (en) * | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
WO2003024455A2 (en) * | 2001-09-17 | 2003-03-27 | Control Delivery Systems, Inc. | Stent coated with a sustained-release drug delivery and method for use thereof |
WO2003030943A1 (en) * | 2001-10-09 | 2003-04-17 | The University Of British Columbia | Compositions comprising hydroxyapatite useful for the administration of therapeutic agents |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3363399A (en) * | 1998-03-27 | 1999-10-18 | President And Fellows Of Harvard College | Aptamer based bacterial inhibition systems (abbis) |
-
2002
- 2002-10-17 CA CA002464131A patent/CA2464131A1/en not_active Abandoned
- 2002-10-17 EP EP02803289A patent/EP1446008A4/en not_active Withdrawn
- 2002-10-17 AU AU2002365136A patent/AU2002365136A1/en not_active Abandoned
- 2002-10-17 JP JP2003560224A patent/JP2005523890A/en active Pending
- 2002-10-17 WO PCT/US2002/033558 patent/WO2003060142A2/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985554A (en) * | 1994-11-02 | 1999-11-16 | Takeda Chemical Industries, Ltd. | Method of probing the function of proteins or peptides encoded by partially sequenced cDNAs by inhibiting protein synthesis with antisense oligonucleotides |
WO1998052614A2 (en) * | 1997-05-21 | 1998-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
US6333194B1 (en) * | 1999-01-19 | 2001-12-25 | The Children's Hospital Of Philadelphia | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
US6395029B1 (en) * | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
US6232068B1 (en) * | 1999-01-22 | 2001-05-15 | Rosetta Inpharmatics, Inc. | Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies |
WO2001024775A1 (en) * | 1999-10-01 | 2001-04-12 | Essentia Biosystems, Inc. | Gel-forming compositions |
WO2003024455A2 (en) * | 2001-09-17 | 2003-03-27 | Control Delivery Systems, Inc. | Stent coated with a sustained-release drug delivery and method for use thereof |
WO2003030943A1 (en) * | 2001-10-09 | 2003-04-17 | The University Of British Columbia | Compositions comprising hydroxyapatite useful for the administration of therapeutic agents |
Non-Patent Citations (4)
Title |
---|
BIGGINS J B ET AL: "A continuous assay for DNA cleavage: the application of break lights to enediynes, iron-dependent agents, and nucleases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 97, no. 25, 5 December 2000 (2000-12-05), pages 13537 - 13542, XP001094000, ISSN: 0027-8424 * |
CASSIDY R A ET AL: "Triplex formation by psoralen-conjugated chimeric oligonucleoside methylphosphonates", BIOCHEMISTRY 25 JUL 2000 UNITED STATES, vol. 39, no. 29, 25 July 2000 (2000-07-25), pages 8683 - 8691, XP002355044, ISSN: 0006-2960 * |
MIYASHIRO H ET AL: "Analysis of the RNase H activity by fluorescence resonance energy transfer.", NUCLEIC ACIDS SYMPOSIUM SERIES. 2000, no. 44, 2000, pages 55 - 56, XP002377139, ISSN: 0261-3166 * |
SOHAIL M ET AL: "Antisense arrays", MOLECULAR CELL BIOLOGY RESEARCH COMMUNICATIONS, vol. 3, no. 2, February 2000 (2000-02-01), pages 67 - 72, XP002377138, ISSN: 1522-4724 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002365136A8 (en) | 2003-07-30 |
WO2003060142A2 (en) | 2003-07-24 |
EP1446008A2 (en) | 2004-08-18 |
CA2464131A1 (en) | 2003-07-24 |
AU2002365136A1 (en) | 2003-07-30 |
WO2003060142A9 (en) | 2003-08-21 |
JP2005523890A (en) | 2005-08-11 |
WO2003060142A3 (en) | 2004-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0218157D0 (en) | Compositions for controlled release | |
AU2002357119A8 (en) | Mitocidal compositions and methods | |
AU2002300377A1 (en) | Compositions for controlled release | |
TWI347202B (en) | Controlled release preparation | |
IL173300A0 (en) | Compositions for encapsulation and controlled release | |
EP1423120A4 (en) | 2h-phthalazin-1-ones and methods for use thereof | |
HUP0301591A3 (en) | Controlled release hydrocodone compositions | |
HK1085387A1 (en) | Controlled release depot formulations | |
IL186782A0 (en) | Controlled release composition and method of producing the same | |
SG84623A1 (en) | Controlled release compositions | |
EP1434772A4 (en) | Compounds and methods | |
EP1476067A4 (en) | Novel compositions and methods for cancer | |
EP1509539A4 (en) | Novel compositions and methods for cancer | |
AU2002357748A8 (en) | Osteopontin-related compositions and methods | |
EP1501352A4 (en) | Methods and compositions for controlled release of drugs | |
EP1469769A4 (en) | Novel compositions and methods for cancer | |
PL364570A1 (en) | Composition and method for controlled release injections | |
AU2002359694A8 (en) | Compounds and methods | |
AU2002365136A8 (en) | Compositions and methods for controlled release | |
EP1469870A4 (en) | Novel compositions and methods for cancer | |
AU2003212866A1 (en) | Controlled release compositions and methods for using same | |
EP1379240A4 (en) | Compounds and methods | |
AU2002359869A8 (en) | Pak5-related compositions and methods | |
GB0107033D0 (en) | Method and composition | |
GB0111389D0 (en) | Controlled release formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040517 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1067848 Country of ref document: HK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/58 20060101ALI20060704BHEP Ipc: C12Q 1/68 20060101ALI20060704BHEP Ipc: C07H 21/04 20060101ALI20060704BHEP Ipc: C07H 21/02 20060101ALI20060704BHEP Ipc: C07H 21/00 20060101ALI20060704BHEP Ipc: A01N 43/04 20060101ALI20060704BHEP Ipc: A01N 37/18 20060101ALI20060704BHEP Ipc: C12Q 1/34 20060101AFI20060704BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060714 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: REVANCE THERAPEUTICS, INC. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: REVANCE THERAPEUTICS, INC. |
|
17Q | First examination report despatched |
Effective date: 20070326 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DAKE, MICHAEL, D. Inventor name: WAUGH, JACOB, M. Inventor name: WONG, ARTHUR, H. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090501 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1067848 Country of ref document: HK |